Biotech firm Windtree Therapeutics has announced plans to buy up to $700 million worth of BNB, the fifth-largest cryptocurrency, following its recent all-time high of $808. The company, listed on Nasdaq under the ticker WINT, aims to enhance its balance sheet with this digital asset by raising $520 million specifically for BNB acquisitions. Windtree has partnered with crypto exchange Kraken for asset custody. The funding will be obtained through a $500 million equity line of credit from an unnamed institutional investor and a $20 million stock-purchase agreement with Build and Build Corp. Windtree's CEO, Jed Latkin, emphasized the importance of stockholder approval for securing these funds. The announcement follows a broader trend of publicly traded companies investing in cryptocurrencies, with other firms like Nano Labs also planning substantial BNB purchases. Windtree's stock experienced a significant rise over the past month despite a slight dip of 5% on the latest bench mark day.

Source đź”—